Earnings Call/Transcript
OSEL Devices Reports Investor Call Recording
OSEL Devices Limited shared the audio recording of its investor call on financial results for the half year ended September 30, 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
3
Neutral
6
Bullish
5
Bearish
35
Neutral
6
Bullish
5
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Investor Presentation
Q2 FY27
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Healthcare Equipment & Supplies
Medical Equipment & Supplies
656 Cr
High Risk
20.4
60.5
0.3
3.2
835.00
320.00
Sales CAGR
Profit CAGR
ROE
ROCE
Earnings Call/Transcript
OSEL Devices Limited shared the audio recording of its investor call on financial results for the half year ended September 30, 2026.
Investor Presentation
Osel Devices presented H1 FY27 results, reporting 31.8% revenue growth, 31.9% EBITDA growth and 19.1% profit growth year over year.
Regulatory/Compliance Filing
Osel Devices Limited reported no deviation or variation in the utilisation of IPO and preferential issue proceeds for the half year ended September 30, 2026.
AGM/EGM Notice
OSEL Devices Limited held its Extraordinary General Meeting on November 12, 2026, through video conferencing. Members considered a special resolution for issuing convertible warrants on a preferential basis.
AGM/EGM Notice
Osel Devices Limited submitted the minutes, scrutinizer’s report and voting results for its November 12, 2026 EGM, where shareholders approved the issue of convertible warrants on a preferential basis.
Financial Results
Osel Devices approved unaudited standalone and consolidated financial results for the half year ended September 30, 2026, and appointed Harsh Garg as CFO effective November 19, 2026.
OSEL Devices Ltd (OSELDEVICE) is currently trading at 345.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Osel Devices Limited designs, manufactures, installs and services LED displays, hearing aids and Philips-branded mobile devices in India, with manufacturing centred in Greater Noida. Its integrated model spans product engineering, local assembly, software, distribution, clinics and after-sales support across electronics and medical-device markets. H1 FY27 revenue increased 31.8% to ₹193.6 crore, while EBITDA rose 31.9% to ₹32.5 crore with the margin stable at 16.8%. However, PAT grew more slowly at 19.1% because finance costs and depreciation increased, highlighting that operating growth has not yet translated proportionately into bottom-line expansion. The company is deliberately moving closer to end customers: hearing aids through 41 SFL clinics, LED displays through CMS subscriptions and a Bharat Mandapam concession, and mobile phones through the Philips brand. This transition could improve revenue quality and margins, but execution and working-capital discipline will be important. Mobile phones already represented approximately 27% of H1 FY27 revenue, supported by 268 distributors and more than 13,800 touchpoints. The Philips S7221 5G launch expands Osel’s addressable market beyond feature phones, while expected tablets could increase wallet share across an existing distribution network. Cash generation remains a key watchpoint despite strong reported growth. H1 FY27 operating cash flow was negative ₹7.6 crore, investing cash flow was negative ₹48.0 crore, receivables and other current assets rose substantially, and short-term borrowings increased to ₹145.3 crore by September 2026.
Over the past 52 weeks, OSEL Devices Ltd has traded between a low of ₹320.00 and a high of ₹835.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
OSEL Devices Ltd has a market capitalization of approximately 656.35. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
OSEL Devices Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.44 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 656.35 Cr, OSEL Devices Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
OSEL Devices Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of OSEL Devices Ltd is 20.44. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
OSEL reported profit after tax of Rs 18.08 crore, but working-capital changes consumed Rs 43.35 crore in H1 FY27. That exceeded the Rs 35.71 crore operating profit before working-capital changes, resulting in negative operating cash flow of Rs 7.65 crore.
OSEL expects the Bharat Mandapam concession to generate about Rs 15 crore of annual revenue. The presentation describes this as an expectation, not revenue already reported in H1 FY27.
OSEL reported revenue from operations of Rs 193.6 crore in H1 FY27, compared with Rs 146.9 crore in H1 FY26. The company reported year-on-year growth of 31.8% and said mobile led the increase.
OSEL says the clinic channel connects it directly with patients through testing, fitting and aftercare. Management describes this move from tender-led supply toward patient relationships as its biggest margin lever. The presentation does not disclose the number of devices sold through clinics in H1 FY27.